MedPath

Prospective study of tansarterial embolization for hepatocellular carcinoma with Lipiodol added Lecithin.

Phase 3
Conditions
hepatocellar carcinoma
Registration Number
JPRN-UMIN000004312
Lead Sponsor
Tokyo Women's Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1:The patient with the anamnesis of the drug hypersensitivity. 2:The patient with contraindication of medication(Hydrochloric acid doxorubicin, Lipiodol, Gelpert and lecithin). 3:The patient with contraindication of TAE. a.Severe liver failure b.Serum Bilirubin(T-Bil):T-Bil>3mg/dl c.Large quantities of acites. 4:The patient having the activity-related infectious disease(more than fever 38.0 degrees ).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
curative effect,response rate,survival time, survival rate
Secondary Outcome Measures
NameTimeMethod
adverse events
© Copyright 2025. All Rights Reserved by MedPath